First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap

Real-world LMIC data demonstrated comparable effectiveness of pembrolizumab-based therapy in a/mNSCLC despite a higher proportion of adverse prognostic factors. More studies in diverse clinical settings are needed to provide a reliable estimate of benefit.